Goldman Sachs reiterates Buy on FMC stock after Q1 beat

FMC beat first-quarter expectations with adjusted EBITDA of $72 million versus $50 million consensus, and revenue of $759 million versus $745.2 million expected. Goldman Sachs reiterated a Buy rating and $21 price target, implying about 37% upside from the current $15.38 share price. While Q2 EBITDA guidance of $130 million to $150 million came in below the $177 million consensus, the company held full-year 2026 EBITDA guidance of $670 million to $730 million, which should help reassure investors.

Analysis

The key read-through is not the quarter itself, but the calibration of the turn. FMC is signaling that pricing pressure is still a headwind, yet the business appears to be reaching a trough where volume stabilization and mix improvement can offset residual deflation; that usually matters more for equity than near-term earnings beats. The market is likely underestimating how much of the downside is already embedded if management can simply avoid another reset over the next 1-2 quarters.

Second-order, the constructive order book in Latin America and share gains in a key crop protection franchise suggest FMC may be taking share in categories where distributors are re-stocking ahead of the next planting cycle. That favors suppliers with better channel access and product continuity, while pressuring smaller regional competitors that rely on price to defend share. If this share gain persists, the earnings power inflection could arrive faster than consensus expects, because operating leverage in agrochem is steep once volumes stop leaking.

The main risk is that the market is extrapolating a turnaround from one clean quarter while the company itself is still guiding below the Street for the next one. If second-quarter volumes disappoint or pricing worsens, the stock can re-rate lower quickly because the narrative support is fragile and heavily consensus-sensitive. A failure to prove sequential stabilization by late summer would push the equity back into a simple value trap frame, regardless of longer-dated optimism.

The contrarian angle is that the equity may be less attractive as a standalone long than as a relative value long versus higher-multiple ag inputs or a short against names with similar end-demand but less visible share gains. The better setup is likely to buy confirmation, not anticipation: if the company prints another quarter with EBITDA above the low end of guidance and no incremental cut to full-year numbers, the rerating could be sharp. Until then, the stock is trading more on credibility repair than on normalized earnings power.

Key Decisions for Investors

• Initiate a tactical long FMC only on confirmation of sequential stabilization: buy on a close above the post-earnings range high, targeting a 15-20% rerate if management holds FY guidance into the next print; stop if channel checks imply Q2 volumes miss again.
• Pair trade: long FMC / short a higher-multiple ag input peer with less evidence of share gain over the next 1-3 months; this isolates the recovery narrative while reducing sector beta if crop input sentiment weakens.
• Sell downside protection in FMC only for investors already long the name: write 1-2 month puts below current trading levels to monetize elevated event risk while the market digests the guidance reset.
• Avoid chasing the stock into the next quarter unless Latin America reorder data and volume trends improve; the downside from another guidance cut likely outweighs near-term upside, implying poor risk/reward for outright longs before confirmation.